Serveur d'exploration Tocilizumab - Exploration (Accueil)

Index « MeshFr.i » - entrée « Produits biologiques »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Produits antisolaires < Produits biologiques < Produits de contraste  Facettes :

List of bibliographic references indexed by Produits biologiques

Number of relevant bibliographic references: 255.
[0-20] [0 - 20][0 - 50][20-40]
Ident.Authors (with country if any)Title
000634 (2019) Ariane Klein [Allemagne][Biologics in the treatment of juvenile idiopathic arthritis : A comparison of mono- and combination therapy with synthetic DMARDs].
000653 (2019) Lianne Kearsley-Fleet [Royaume-Uni] ; Sunil Sampath [Royaume-Uni] ; Liza J. Mccann [Royaume-Uni] ; Eileen Baildam [Royaume-Uni] ; Michael W. Beresford [Royaume-Uni] ; Rebecca Davies [Royaume-Uni] ; Diederik De Cock [Royaume-Uni] ; Helen E. Foster [Royaume-Uni] ; Taunton R. Southwood [Royaume-Uni] ; Wendy Thomson [Royaume-Uni] ; Kimme L. Hyrich [Royaume-Uni]Use and effectiveness of rituximab in children and young people with juvenile idiopathic arthritis in a cohort study in the United Kingdom.
000760 (2019) Francesco Ursini [Italie] ; Piero Ruscitti [Italie] ; Giacomo Pietro Ismaele Caio [Italie] ; Roberto Manfredini [Italie] ; Roberto Giacomelli [Italie] ; Roberto De Giorgio [Italie]The effect of non-TNF-targeted biologics on vascular dysfunction in rheumatoid arthritis: A systematic literature review.
000880 (2019) Ajinkya Pawar [États-Unis] ; Rishi J. Desai [États-Unis] ; Daniel H. Solomon [États-Unis] ; Adrian J. Santiago Ortiz [États-Unis] ; Sara Gale [États-Unis] ; Min Bao [États-Unis] ; Khaled Sarsour [États-Unis] ; Sebastian Schneeweiss [États-Unis] ; Seoyoung C. Kim [États-Unis]Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study.
000888 (2019) Michael D. George ; Joshua F. Baker ; Kevin Winthrop [États-Unis] ; Evo Alemao ; Lang Chen ; Sean Connolly ; Jesse Y. Hsu ; Teresa A. Simon ; Qufei Wu ; Fenglong Xie ; Shuo Yang ; Jeffrey R. CurtisRisk of Biologics and Glucocorticoids in Patients With Rheumatoid Arthritis Undergoing Arthroplasty: A Cohort Study.
000892 (2019) Kenji Oku [Japon] ; Tatsuya Atsumi [Japon]Rheumatology practice in Japan: challenges and opportunities.
000894 (2019) Emma L. Simpson [Royaume-Uni] ; Shijie Ren [Royaume-Uni] ; Emma S. Hock [Royaume-Uni] ; John W. Stevens [Royaume-Uni] ; Aymeric Binard [France] ; Yves-Marie Pers [France] ; Rachel Archer [Royaume-Uni] ; Suzy Paisley [Royaume-Uni] ; Matthew D. Stevenson [Royaume-Uni] ; Chloé Herpin [France] ; Salah Ghabri [France]Rheumatoid arthritis treated with 6-months of first-line biologic or biosimilar therapy: an updated systematic review and network meta-analysis.
000930 (2019) Durga Prasanna Misra [Inde] ; Anupam Wakhlu [Inde] ; Vikas Agarwal [Inde] ; Debashish Danda [Inde]Recent advances in the management of Takayasu arteritis.
000950 (2019) Kenan Barut [Turquie] ; Amra Adrovic [Turquie] ; Sezgin Sahin [Turquie] ; Gurkan Tarcin [Turquie] ; Gulberk Tahaoglu [Turquie] ; Oya Koker [Turquie] ; Mehmet Yildiz [Turquie] ; Ozgur Kasapcopur [Turquie]Prognosis, complications and treatment response in systemic juvenile idiopathic arthritis patients: A single-center experience.
000954 (2019) Diederik De Cock [Belgique] ; Patrick Verschueren [Belgique]Primus inter pares: the choice of biologic drugs in rheumatoid arthritis.
000966 (2019) Meghna Jani [Royaume-Uni] ; Anne Barton [Royaume-Uni] ; Kimme Hyrich [Royaume-Uni]Prediction of infection risk in rheumatoid arthritis patients treated with biologics: are we any closer to risk stratification?
000A50 (2019) Manuel Camean-Castillo [Espagne] ; Vicente Gimeno-Ballester [Espagne] ; Esmeralda Rios-Sanchez [Espagne] ; Silvia Fenix-Caballero [Espagne] ; Miguel Vázquez-Real [Espagne] ; Emilio Alegre-Del Rey [Espagne]Network meta-analysis of tofacitinib versus biologic treatments in moderate-to-severe rheumatoid arthritis patients.
000A88 (2019) Carlo Salvarani [Italie] ; Gulen Hatemi [Turquie]Management of large-vessel vasculitis.
000B14 (2019) Francisco Airton Castro Rocha [Brésil] ; Joaquim Ivo Vasques Dantas Landim [Brésil] ; Mariana Lima Nour [Brésil] ; Valdenir Freire Peixoto Filho [Brésil] ; Leila Nascimento Da Rocha [Brésil] ; Marco Felipe Castro Da Silva [Brésil] ; Hermano Alexandre Lima Rocha [Brésil]Long-term breastfeeding influences disease activity in a low-income juvenile idiopathic arthritis cohort.
000B89 (2019) Juan Shan [République populaire de Chine] ; Jiabi Zhang [République populaire de Chine]Impact of obesity on the efficacy of different biologic agents in inflammatory diseases: A systematic review and meta-analysis.
000D54 (2019) Kosuke Ebina [Japon] ; Motomu Hashimoto [Japon] ; Wataru Yamamoto [Japon] ; Toru Hirano [Japon] ; Ryota Hara [Japon] ; Masaki Katayama [Japon] ; Akira Onishi [Japon] ; Koji Nagai [Japon] ; Yonsu Son [Japon] ; Hideki Amuro [Japon] ; Keiichi Yamamoto [Japon] ; Yuichi Maeda [Japon] ; Koichi Murata [Japon] ; Sadao Jinno [Japon] ; Tohru Takeuchi [Japon] ; Makoto Hirao [Japon] ; Atsushi Kumanogoh [Japon] ; Hideki Yoshikawa [Japon]Drug tolerability and reasons for discontinuation of seven biologics in elderly patients with rheumatoid arthritis -The ANSWER cohort study-
000E02 (2019) Sofia Kourkounti [Grèce] ; Vasilios Paparizos [Grèce] ; Theodoros Retsas [Grèce] ; Amerini Dimitrakopoulou [Grèce] ; Dimitrios Rigopoulos [Grèce]Cutaneous vasculitis in HIV-associated Castleman's disease: a rare manifestation.
000E39 (2019) C. Diener [Allemagne] ; G. Horneff [Allemagne]Comparison of adverse events of biologicals for treatment of juvenile idiopathic arthritis: a systematic review.
000E42 (2019) Katsuhiko Takabayashi [Japon] ; Fumihiko Ando [États-Unis] ; Takahiro Suzuki [Japon]Comparing the effectiveness of biological disease-modifying antirheumatic drugs using real-world data.
000E52 (2019) Thomas Frisell [Suède] ; Johan Askling [Suède]Comment on: Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: results from the nationwide Swedish register: reply.
000E53 (2019) Thomas Frisell [Suède] ; Johan Askling [Suède]Comment on: Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: results from the nationwide Swedish register: reply.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/MeshFr.i -k "Produits biologiques" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/MeshFr.i  \
                -Sk "Produits biologiques" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    MeshFr.i
   |clé=    Produits biologiques
}}

Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021